GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Net Income Including Noncontrolling Interests

Summit Therapeutics (LSE:SUMM) Net Income Including Noncontrolling Interests : £-91.94 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Summit Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was £-34.21 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was £-91.94 Mil.

Summit Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Summit Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Net Income Including Noncontrolling Interests Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.42 -39.21 -66.63 -64.68 -485.79

Summit Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -446.92 -11.66 -17.19 -28.89 -34.21

Summit Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-91.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (LSE:SUMM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
CGON ARWR MLTX ACAD APGE ACLX MRUS JANX IDYA CLDX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SMMT:USA
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Website
https://www.smmttx.com
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines